Weight loss | A new anti-obesity drug that also lowers blood cholesterol arrives in pharmacies

Weight loss |  A new anti-obesity drug that also lowers blood cholesterol arrives in pharmacies

A new anti-obesity drug that also lowers blood cholesterol arrives in pharmaciesEPC

Market accessOzimbekthe trade name of semaglutidaIt was a real revolution for patients suffering from obesity. It is that even though it is a medicine that helps improve Blood sugar levelsbecame famous because Helps lose weight Or rather, it enhances the feeling of fullness.

And this medicine has one New competitor. As of next July 1, it will be sold in pharmacies Monjaro (whose active principle is la In Terzpati), of weekly subcutaneous administration that is approved for two indications: as a treatment for Type 2 diabetes for Weight control.

It can only be managed Under prescription Unlike Ozempic, it is not funded by the Ministry of Health. Monjaro, which joins the other two available for obesity, has one Cost Menual to 271 euros For maintenance doses.

For which patients is this new medicine prescribed?

Seconds Laylathe company bringing it to the market, is the first drug in a new therapeutic family that acts on the GIP and GLP-1 receptors.

Its mechanism of action, in addition to its preference Monitor blood sugarmakes it so Decreased appetiteIncrease the feeling of fullness and reduce excess fat, including visceral fat around the waist.

It is the first anti-obesity drug with a dual connotation. On the one hand, terzepatide is approved to treat “inadequately” controlled type 2 diabetes, and on the other hand, for weight control in people over 18 years of age:

  • With a body mass index (BMI) greater than or equal to 27 and at least one complication resulting from excess weight.

  • Patients with obesity (BMI > 30) which should be combined with a low-calorie diet and physical activity.

In people with type 2 diabetes (which usually appears after age 40), this medication improves blood sugar control through multiple mechanisms including increased insulin secretion, decreased glucagon secretion, and improved insulin sensitivity.

23 kilos less in 16 months

In overweight and obese subjects who did not have diabetes, tirizpatide showed an average weight loss of 22.5% (23.6 kg) at week 72. In addition, 4 out of 10 patients achieved weight loss equal to or greater than 25%.

All this, as the pharmaceutical company emphasizes, with a high response rate: 96% of patients achieved a reduction equal to or greater than 5% after 72 weeks of treatment.

The doctor stressed that patients who are overweight or obese without having diabetes Javier EscaladaPresident of the Foundation of the Spanish Society of Endocrinology and Nutrition (FSEEN):

  • “The powerful effect of the molecule in terms of blood sugar control has been demonstrated, resulting in normalization of HbA1c levels in up to 51% of people treated with DM2, and weight loss with a reduction of about 20% at doses of 10 and 15 mg. / A week in obesity.

  • “These data are close to what is achieved after bariatric surgery. Besides, beneficial effects on various cardiovascular risk factors are targeted, although the specific results of cardiovascular effects will be known later.”

Obesity is a chronic disease

the doctor Malagon Seapresident Spanish Society of Obesity (SEEDO), explained during Mongaro’s presentation that “obesity is a recurring chronic disease that affects more than 18% of the adult population in Spain. Scientific evidence shows that it is one A complex and multifactorial diseasewhich they influence Biological and genetic factors fins a Social, economic and environmental factors Or hours.”

The specialist emphasized that research was also essential in identifying the fundamental factors that regulate food intake and body weight, “which served as the basis for developing compounds with therapeutic benefit that open the door to optimism for people suffering from this disease.” .

In addition, people who are obese are more likely to suffer from “More than 200 complications“, as the doctor confirmed Alfredo Mishan DoñaInternal Medicine Specialist and Coordinator of the Diabetes, Obesity and Nutrition Group at Spanish Society of Internal Medicine (half):

  • Cardiovascular diseases

  • Type 2 diabetes

  • Fat changes

  • Metabolic liver disease (the number one cause of cirrhosis in our country)

  • Chronic respiratory diseases

  • Infertility

  • Without forgetting the most common cancers: breast, colorectal, kidney, liver, ovary…

Tirzepatide: It also improves cholesterol levels and high blood pressure

In addition to weight control, in participants who participated in this clinical trial, a benefit was observed with tirzepatide in key cardiometabolic parameters:

  • Producing reductions in waist circumference ranging from 14.6 to 19.9 cm, a decrease in triglycerides (24.3 – 31.4%), a decrease in blood pressure (both systolic and diastolic) and a positive effect on cholesterol levels (with improvements in HDL and a decrease in LDL).

But to the doctor Jose Antonio Sacristan“, Medical Director of Lilly Spain, “The commercialization of terzepatide represents a major milestone in the treatment of people with type 2 diabetes and obesity. that it Disruptive innovationThis reflects Lily’s mission to research and develop medicines that represent a qualitative shift in the treatment of diseases that affect hope and quality of life for patients.

See also  Pistoletto and Paolini, guides for the Genoa Science Festival

Leave a Reply

Your email address will not be published. Required fields are marked *